Drug Trial Radar · NCT07584135
JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
May 28, 2026
Primary completion
Jan 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- NingBo Junyan Hongshi Biosciences Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- May 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, open-label, controlled Phase III clinical trial aimed at evaluating the efficacy and safety of JS107 combined with toripalimab XELOX versus sintilimab combined with XELOX as first-line treatment for patients with advanced G/GEJ adenocarcinoma. The research subjects were patients with unresectable locally advanced, recurrent or metastatic G/GEJ adenocarcinoma who were CLDN18.2-positive and HER2-negative and had not received systemic treatment before (except for neoadjuvant/adjuvant therapy that occurred more than 6 months after disease progression/recurrence from the last treatment). The study took BICR-PFS and OS as Dual primary endpoints.
Conditions
- Gastric Adenocarcinoma
Interventions
Injection JS107&Toripalimab& Oxaliplatin Injection& CapecitabineDrug
JS107: 2 mg/kg on day 1 Q3W; Toripalimab (T): 240 mg on day 1 Q3W. Capecitabine (C): 750 mg/m² BID Day1-Day14, Q3W,Oxaliplatin 100mg/m² on Day1 Q3W, Maximum of 6 cycles.
Sintilimab& Oxaliplatin Injection& CapecitabineDrug
Sintilimab: 3 mg/kg or 200 mg Day1 Q3W, Capecitabine: 1000 mg/m² BID Day1-Day14, Q3W,Oxaliplatin 130mg/m² on Day1 Q3W, Maximum of 6 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- BICR-PFSTime frame: up to 2 years
- Overall SurvivalTime frame: up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.